The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 22, 2007
Filed:
Jul. 26, 2005
Michael J. Hageman, Portage, MI (US);
Xiaorong He, Kalamazoo, MI (US);
Tugrul T. Kararli, Skokie, IL (US);
Lesley A. Mackin, Evanston, IL (US);
Patricia J. Miyake, Tower Lakes, IL (US);
Brian R. Rohrs, Scotts, MI (US);
Kevin J. Stefanski, Kalamazoo, MI (US);
Michael J. Hageman, Portage, MI (US);
Xiaorong He, Kalamazoo, MI (US);
Tugrul T. Kararli, Skokie, IL (US);
Lesley A. MacKin, Evanston, IL (US);
Patricia J. Miyake, Tower Lakes, IL (US);
Brian R. Rohrs, Scotts, MI (US);
Kevin J. Stefanski, Kalamazoo, MI (US);
Pharmacia Corporation (of Pfizer, Inc.), St. Louis, MO (US);
Abstract
The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.